Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | C15orf48 | Human | (+)-catechin | multiple interactions | EXP | | 6480464 | [Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of C15ORF48 mRNA | CTD | PMID:24763279 | C15orf48 | Human | (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C15ORF48 mRNA | CTD | PMID:22079256 | C15orf48 | Human | 2-hydroxypropanoic acid | decreases expression | EXP | | 6480464 | Lactic Acid results in decreased expression of C15ORF48 mRNA | CTD | PMID:30851411 | C15orf48 | Human | 4,4'-sulfonyldiphenol | decreases expression | EXP | | 6480464 | bisphenol S results in decreased expression of C15ORF48 mRNA | CTD | PMID:25912373 | C15orf48 | Human | 4-hydroxyphenyl retinamide | increases expression | ISO | AA467197 (Mus musculus) | 6480464 | Fenretinide results in increased expression of C15ORF48 mRNA | CTD | PMID:28973697 | C15orf48 | Human | 5-aza-2'-deoxycytidine | multiple interactions | EXP | | 6480464 | [Decitabine affects the methylation of NMES1 promoter] which affects the expression of NMES1 protein | CTD | PMID:18636205 | C15orf48 | Human | aflatoxin B1 | affects expression | EXP | | 6480464 | Aflatoxin B1 affects the expression of C15ORF48 protein | CTD | PMID:20106945 | C15orf48 | Human | all-trans-retinoic acid | increases expression | EXP | | 6480464 | Tretinoin results in increased expression of C15ORF48 mRNA | CTD | PMID:23830798 | C15orf48 | Human | antirheumatic drug | decreases expression | EXP | | 6480464 | Antirheumatic Agents results in decreased expression of C15ORF48 mRNA | CTD | PMID:24449571 | C15orf48 | Human | aristolochic acid A | increases expression | EXP | | 6480464 | aristolochic acid I results in increased expression of C15ORF48 mRNA | CTD | PMID:33212167 | C15orf48 | Human | arsane | multiple interactions | EXP | | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of C15ORF48 mRNA | CTD | PMID:32525701 | C15orf48 | Human | arsenic atom | multiple interactions | EXP | | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of C15ORF48 mRNA | CTD | PMID:32525701 | C15orf48 | Human | arsenous acid | increases expression | EXP | | 6480464 | Arsenic Trioxide results in increased expression of NMES1 mRNA | CTD | PMID:20458559 | C15orf48 | Human | arsenous acid | decreases expression | EXP | | 6480464 | Arsenic Trioxide results in decreased expression of C15ORF48 mRNA | CTD | PMID:19128835 | C15orf48 | Human | atrazine | increases expression | EXP | | 6480464 | Atrazine results in increased expression of C15ORF48 mRNA | CTD | PMID:18461179 | C15orf48 | Human | benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of NMES1 protein | CTD | PMID:32717239 | C15orf48 | Human | benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzo(a)pyrene results in increased expression of C15ORF48 mRNA | CTD | PMID:32234424 | C15orf48 | Human | benzo[a]pyrene | decreases methylation | EXP | | 6480464 | Benzo(a)pyrene results in decreased methylation of C15ORF48 promoter | CTD | PMID:27901495 | C15orf48 | Human | benzo[a]pyrene diol epoxide I | increases expression | EXP | | 6480464 | 7 more ... | CTD | PMID:20382639 | C15orf48 | Human | bis(2-chloroethyl) sulfide | increases expression | EXP | | 6480464 | Mustard Gas results in increased expression of C15ORF48 mRNA | CTD | PMID:25102026 | C15orf48 | Human | bis(2-ethylhexyl) phthalate | increases expression | EXP | | 6480464 | Diethylhexyl Phthalate results in increased expression of C15ORF48 mRNA | CTD | PMID:31163220 | C15orf48 | Human | bisphenol A | increases expression | ISO | C3h15orf48 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of C15ORF48 mRNA | CTD | PMID:25181051 | C15orf48 | Human | bosentan | affects expression | EXP | | 6480464 | Bosentan affects the expression of C15ORF48 mRNA | CTD | PMID:29761207 | C15orf48 | Human | butanal | increases expression | EXP | | 6480464 | butyraldehyde results in increased expression of C15ORF48 mRNA | CTD | PMID:26079696 | C15orf48 | Human | cholesterol | increases expression | EXP | | 6480464 | Cholesterol results in increased expression of C15ORF48 mRNA | CTD | PMID:26296894 | C15orf48 | Human | chromium(6+) | decreases expression | EXP | | 6480464 | chromium hexavalent ion results in decreased expression of C15ORF48 mRNA | CTD | PMID:30690063 | C15orf48 | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of C15ORF48 mRNA | CTD | PMID:27392435 | C15orf48 | Human | crocidolite asbestos | increases expression | EXP | | 6480464 | Asbestos and Crocidolite results in increased expression of C15ORF48 mRNA | CTD | PMID:18687144 | C15orf48 | Human | cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of C15ORF48 mRNA | CTD | PMID:27989131 | C15orf48 | Human | diarsenic trioxide | increases expression | EXP | | 6480464 | Arsenic Trioxide results in increased expression of NMES1 mRNA | CTD | PMID:20458559 | C15orf48 | Human | diarsenic trioxide | decreases expression | EXP | | 6480464 | Arsenic Trioxide results in decreased expression of C15ORF48 mRNA | CTD | PMID:19128835 | C15orf48 | Human | entinostat | increases expression | EXP | | 6480464 | entinostat results in increased expression of C15ORF48 mRNA | CTD | PMID:27188386 | C15orf48 | Human | genistein | decreases expression | EXP | | 6480464 | Genistein results in decreased expression of C15ORF48 mRNA | CTD | PMID:20884965 | C15orf48 | Human | hydrogen peroxide | affects expression | EXP | | 6480464 | Hydrogen Peroxide affects the expression of NMES1 mRNA | CTD | PMID:20044591 | C15orf48 | Human | hydroquinone | increases expression | EXP | | 6480464 | hydroquinone results in increased expression of C15ORF48 mRNA | CTD | PMID:31256213 | C15orf48 | Human | lipopolysaccharide | increases expression | EXP | | 6480464 | Lipopolysaccharides results in increased expression of C15ORF48 mRNA | CTD | PMID:18192897 and PMID:35811015 | C15orf48 | Human | lipopolysaccharide | multiple interactions | EXP | | 6480464 | [S-(1 more ... | CTD | PMID:35811015 | C15orf48 | Human | malathion | increases expression | EXP | | 6480464 | Malathion results in increased expression of C15ORF48 mRNA | CTD | PMID:37047231 | C15orf48 | Human | medroxyprogesterone acetate | decreases expression | EXP | | 6480464 | Medroxyprogesterone Acetate results in decreased expression of C15ORF48 mRNA | CTD | PMID:20843944 | C15orf48 | Human | nickel atom | increases expression | EXP | | 6480464 | Nickel results in increased expression of C15ORF48 mRNA | CTD | PMID:23195993 | C15orf48 | Human | nickel dichloride | increases expression | EXP | | 6480464 | nickel chloride results in increased expression of C15ORF48 mRNA | CTD | PMID:21455298 | C15orf48 | Human | nickel sulfate | increases expression | EXP | | 6480464 | nickel sulfate results in increased expression of C15ORF48 mRNA | CTD | PMID:25673294 | C15orf48 | Human | ozone | increases expression | EXP | | 6480464 | Ozone results in increased expression of NMES1 mRNA | CTD | PMID:23033980 | C15orf48 | Human | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of C15ORF48 mRNA | CTD | PMID:26690555 | C15orf48 | Human | pentanal | increases expression | EXP | | 6480464 | pentanal results in increased expression of C15ORF48 mRNA | CTD | PMID:26079696 | C15orf48 | Human | phorbol 13-acetate 12-myristate | affects expression | ISO | AA467197 (Mus musculus) | 6480464 | Tetradecanoylphorbol Acetate affects the expression of NMES1 | CTD | PMID:16044405 | C15orf48 | Human | phorbol 13-acetate 12-myristate | affects response to substance | ISO | AA467197 (Mus musculus) | 6480464 | NMES1 affects the susceptibility to Tetradecanoylphorbol Acetate | CTD | PMID:16044405 | C15orf48 | Human | potassium chromate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of C15ORF48 mRNA | CTD | PMID:22079256 | C15orf48 | Human | potassium chromate | decreases expression | EXP | | 6480464 | potassium chromate(VI) results in decreased expression of C15ORF48 mRNA | CTD | PMID:22079256 and PMID:22714537 | C15orf48 | Human | propanal | increases expression | EXP | | 6480464 | propionaldehyde results in increased expression of C15ORF48 mRNA | CTD | PMID:26079696 | C15orf48 | Human | quercetin | increases expression | EXP | | 6480464 | Quercetin results in increased expression of C15ORF48 mRNA | CTD | PMID:21632981 | C15orf48 | Human | rac-lactic acid | decreases expression | EXP | | 6480464 | Lactic Acid results in decreased expression of C15ORF48 mRNA | CTD | PMID:30851411 | C15orf48 | Human | resveratrol | increases expression | EXP | | 6480464 | resveratrol results in increased expression of C15ORF48 mRNA | CTD | PMID:17257620 | C15orf48 | Human | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | EXP | | 6480464 | [S-(1 more ... | CTD | PMID:35811015 | C15orf48 | Human | silicon dioxide | increases expression | EXP | | 6480464 | Silicon Dioxide analog results in increased expression of C15ORF48 mRNA | CTD | PMID:25895662 | C15orf48 | Human | silver atom | increases expression | EXP | | 6480464 | Silver results in increased expression of C15ORF48 mRNA | CTD | PMID:28959546 | C15orf48 | Human | silver(0) | increases expression | EXP | | 6480464 | Silver results in increased expression of C15ORF48 mRNA | CTD | PMID:28959546 | C15orf48 | Human | sodium arsenate | multiple interactions | EXP | | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of C15ORF48 mRNA | CTD | PMID:32525701 | C15orf48 | Human | sotorasib | multiple interactions | EXP | | 6480464 | [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of C15ORF48 mRNA | CTD | PMID:36139627 | C15orf48 | Human | trametinib | multiple interactions | EXP | | 6480464 | [sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of C15ORF48 mRNA | CTD | PMID:36139627 | C15orf48 | Human | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of C15ORF48 mRNA | CTD | PMID:25979313 | C15orf48 | Human | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of C15ORF48 mRNA | CTD | PMID:23179753 more ... | C15orf48 | Human | zoledronic acid | increases expression | EXP | | 6480464 | zoledronic acid results in increased expression of C15ORF48 mRNA | CTD | PMID:24714768 | |